Logo

Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar- aflibercept)

Share this

Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar- aflibercept)

Shots:

  • BIOEQ will sponsor the P-III study which will assess the FYB203 vs Eylea in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy- safety and immunogenicity. Additionally- the design of the study is developed in collaboration with the USFDA- EMA- PMDA
  • The second program in ophthalmology will aim to strengthen and expand the footprints in ophthalmologic biosimilars
  • FYB203 is a biosimilar to Eylea (aflibercept) human fusion protein works by binding to VEGF-A- targeted for neovascular age-related macular degeneration (nAMD) including serious eye diseases. In 2015- Formycon AG signed an exclusive global license agreement with Santo Holding (Deutschland) GmbH for FYB203

Ref: Formycon | Image: Behance

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions